{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:25:35Z","timestamp":1787030735302,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare the long-term efficacy and safety of zoledronic acid versus denosumab in the treatment of primary osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study analyzed 328 patients diagnosed with primary osteoporosis at the Department of Rheumatology and Immunology, Changhai Hospital, between January 2017 and December 2020. After applying inclusion and exclusion criteria, 164 patients were enrolled and divided into the zoledronic acid group (n = 88) and the denosumab group (n = 76). Bone mineral density (BMD) at the lumbar spine (L1\u2013L4) and hip, bone turnover markers (including bone alkaline phosphatase, serum C-terminal telopeptide of type I collagen, and serum N-terminal propeptide of type I procollagen), and adverse events were evaluated at baseline and at 1, 2, and 3 years post-treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, the two groups exhibited no statistically significant differences in most parameters except for parathyroid hormone (PTH), lumbar spine BMD, and lumbar T-score. After three years of treatment, denosumab demonstrated superior efficacy compared to zoledronic acid in key outcome measures, including lumbar spine BMD (0.85 \u00b1 0.17 vs. 0.81 \u00b1 0.14), hip BMD (0.85 \u00b1 0.13 vs. 0.79 \u00b1 0.12), and \u03b2-CTX (0.27 \u00b1 0.19 vs. 0.38 \u00b1 0.23), with statistically significant differences (P &amp;lt; 0.05). Both treatments demonstrated favorable safety profiles, with no serious adverse events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Denosumab exhibits superior long-term efficacy over zoledronic acid in improving bone mineral density and suppressing bone turnover. Both agents demonstrate excellent safety profiles and represent effective therapeutic options for the management of osteoporosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1825856","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:05Z","timestamp":1787027345000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of zoledronic acid versus denosumab in the treatment of primary osteoporosis: a single-center retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Xuan","family":"Li","sequence":"first","affiliation":[{"name":"Fangta Traditional Chinese Medicine Hospital of Songjiang District of Shanghai","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejia","family":"Huang","sequence":"additional","affiliation":[{"name":"School of Basic Medical Sciences, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeqing","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhe","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongbao","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, First Affiliated Hospital of Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/8756-3282(95)00258-4","article-title":"The worldwide problem of osteoporosis: insights afforded by epidemiology","volume":"17","author":"Riggs","year":"1995","journal-title":"Bone"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.21106","article-title":"Prevalence of osteoporosis and fracture in China: the China Osteoporosis Prevalence Study","volume":"4","author":"Wang","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.2007.057505","article-title":"The role of DXA bone density scans in the diagnosis and treatment of osteoporosis","volume":"83","author":"Blake","year":"2007","journal-title":"Postgrad Med J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-021-00930-4","article-title":"Practical considerations for the clinical application of bone turnover markers in osteoporosis","volume":"112","author":"Vasikaran","year":"2023","journal-title":"Calcif Tissue Int"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnac031","article-title":"Bone turnover markers: basic biology to clinical applications","volume":"44","author":"Schini","year":"2023","journal-title":"Endocr Rev"},{"key":"B7","article-title":"Biochemical bone turnover markers: significance in patients with osteoporosis","volume":"33","author":"Mihaljevi\u0107","year":"2009","journal-title":"Coll Antropol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: from bench to bedside","volume":"1218","author":"Russell","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2011.585156","article-title":"Pharmacokinetic evaluation of zoledronic acid","volume":"7","author":"De Luca","year":"2011","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00006254-200301000-00020","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11801","DOI":"10.1038\/s41598-021-91248-6","article-title":"Denosumab versus romosozumab for postmenopausal osteoporosis treatment","volume":"11","author":"Kobayakawa","year":"2021","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"key":"B13","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/mjt.0000000000000415","article-title":"Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials","volume":"27","author":"Wang","year":"2023","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-015-3174-2","article-title":"Denosumab versus zoledronic acid in patients previously treated with zoledronic acid","volume":"26","author":"Anastasilakis","year":"2015","journal-title":"Osteoporos Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.25011\/cim.v45i3.38875","article-title":"Denosumab versus bisphosphonates for the prevention of vertebral fractures in men with osteoporosis: an updated network meta-analysis","volume":"45","author":"Li","year":"2022","journal-title":"Clin Invest Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30072-x","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomized, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s11914-022-00771-6","article-title":"Denosumab discontinuation","volume":"21","author":"S\u00f8lling","year":"2023","journal-title":"Curr Osteoporos Rep"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4705","article-title":"Multiple vertebral fractures after denosumab discontinuation: FREEDOM and FREEDOM extension trials additional post hoc analyses","volume":"37","author":"Cosman","year":"2022","journal-title":"J Bone Miner Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/jbmr\/zjaf037","article-title":"Denosumab discontinuation in the clinic: implications of rebound bone turnover and emerging strategies to prevent bone loss and fractures","volume":"40","author":"Kumar","year":"2025","journal-title":"J Bone Miner Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.12114\/j.issn.1007-9572.2023.0121","article-title":"Chinese guidelines for the diagnosis and treatment of primary osteoporosis","volume":"15","year":"2022","journal-title":"Chin J Osteoporos Bone Miner Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1055\/s-0039-1680013","article-title":"Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment","volume":"120","author":"Tsourdi","year":"2019","journal-title":"Bone"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.4065\/83.9.1032","article-title":"Bisphosphonates: mechanism of action and role in clinical practice","volume":"83","author":"Drake","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2022.37.e68","article-title":"Comparison of denosumab and zoledronic acid in postmenopausal women with osteoporosis: bone mineral density (BMD) and trabecular bone score (TBS)","volume":"37","author":"Kang","year":"2022","journal-title":"J Korean Med Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s11657-024-01475-3","article-title":"Effects of denosumab and zoledronic acid on postmenopausal osteoporosis, bone density, and fat-free mass","volume":"20","author":"Ha","year":"2025","journal-title":"Arch Osteoporos"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3019","article-title":"Comparative safety and effectiveness of denosumab versus zoledronic acid in patients with osteoporosis: a cohort study","volume":"32","author":"Choi","year":"2017","journal-title":"J Bone Miner Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13072040","article-title":"Comparison of the efficacy of zoledronate and denosumab in patients with acute osteoporotic vertebral compression fractures: a randomized controlled trial","volume":"13","author":"Son","year":"2024","journal-title":"J Clin Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07118-0","article-title":"Denosumab vs bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials","volume":"35","author":"Kobayashi","year":"2024","journal-title":"Osteoporos Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11657-022-01129-2","article-title":"Safety of denosumab versus zoledronic acid in older adults with osteoporosis: a meta-analysis of cohort studies","volume":"17","author":"Li","year":"2022","journal-title":"Arch Osteoporos"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1825856\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:29:07Z","timestamp":1787027347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1825856\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":29,"alternative-id":["10.3389\/fendo.2026.1825856"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1825856","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1825856"}}